Chimerix Inc
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases in the United States. Its product pipeline comprising dordaviprone (ONC201), which is in phase 3 clinical-stage development for H3 K27M-mutant diffuse glioma, as well as in phase 2 Investigator Initiated Clinical Trials for multiple oncology studies; and ONC206, a sec… Read more
Chimerix Inc (CMRX) - Net Assets
Latest net assets as of March 2025: $121.68 Million USD
Based on the latest financial reports, Chimerix Inc (CMRX) has net assets worth $121.68 Million USD as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($146.01 Million) and total liabilities ($24.33 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $121.68 Million |
| % of Total Assets | 83.34% |
| Annual Growth Rate | 21.49% |
| 5-Year Change | 65.83% |
| 10-Year Change | -63.73% |
| Growth Volatility | 176.3 |
Chimerix Inc - Net Assets Trend (2011–2024)
This chart illustrates how Chimerix Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Chimerix Inc (2011–2024)
The table below shows the annual net assets of Chimerix Inc from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $121.68 Million | -36.96% |
| 2023-12-31 | $193.03 Million | -24.85% |
| 2022-12-31 | $256.86 Million | +276.34% |
| 2021-12-31 | $68.25 Million | -6.98% |
| 2020-12-31 | $73.38 Million | -33.27% |
| 2019-12-31 | $109.95 Million | -38.09% |
| 2018-12-31 | $177.60 Million | -19.93% |
| 2017-12-31 | $221.81 Million | -19.70% |
| 2016-12-31 | $276.22 Million | -17.66% |
| 2015-12-31 | $335.46 Million | +22.15% |
| 2014-12-31 | $274.64 Million | +178.71% |
| 2013-12-31 | $98.54 Million | +593.74% |
| 2012-12-31 | $14.20 Million | +46.64% |
| 2011-12-31 | $9.69 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Chimerix Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 79023300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $92.00K | 0.08% |
| Other Components | $1.01 Billion | 826.35% |
| Total Equity | $121.68 Million | 100.00% |
Chimerix Inc Competitors by Market Cap
The table below lists competitors of Chimerix Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Foshan Saturday Shoes Co Ltd
SHE:002291
|
$687.03 Million |
|
Robinsons Retail Holdings Inc
PINK:RRETY
|
$687.12 Million |
|
CrossFirst Bankshares Inc
NASDAQ:CFB
|
$687.14 Million |
|
SANGETSU CO LTD
OTCGREY:SGSUF
|
$687.16 Million |
|
Kardemir Karabuk Demir Celik Sanayi ve Ticaret AS Class D
IS:KRDMD
|
$686.89 Million |
|
Hunan Changgao High Voltage Switchgear Group Co Ltd
SHE:002452
|
$686.89 Million |
|
GREENTOWN SVC.G.HD-00001
F:GR1
|
$686.73 Million |
|
NextNav Inc. Warrant
NASDAQ:NNAVW
|
$686.53 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Chimerix Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 193,029,000 to 121,679,000, a change of -71,350,000 (-37.0%).
- Net loss of 88,387,000 reduced equity.
- New share issuances of 6,835,000 increased equity.
- Other comprehensive income decreased equity by 7,000.
- Other factors increased equity by 10,209,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-88.39 Million | -72.64% |
| Share Issuances | $6.83 Million | +5.62% |
| Other Comprehensive Income | $-7.00K | -0.01% |
| Other Changes | $10.21 Million | +8.39% |
| Total Change | $- | -36.96% |
Book Value vs Market Value Analysis
This analysis compares Chimerix Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.30x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 8.26x to 6.30x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $1.03 | $8.54 | x |
| 2012-12-31 | $1.52 | $8.54 | x |
| 2013-12-31 | $5.10 | $8.54 | x |
| 2014-12-31 | $8.32 | $8.54 | x |
| 2015-12-31 | $7.65 | $8.54 | x |
| 2016-12-31 | $5.97 | $8.54 | x |
| 2017-12-31 | $4.72 | $8.54 | x |
| 2018-12-31 | $3.65 | $8.54 | x |
| 2019-12-31 | $1.98 | $8.54 | x |
| 2020-12-31 | $1.18 | $8.54 | x |
| 2021-12-31 | $0.80 | $8.54 | x |
| 2022-12-31 | $2.89 | $8.54 | x |
| 2023-12-31 | $2.18 | $8.54 | x |
| 2024-12-31 | $1.36 | $8.54 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Chimerix Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -72.64%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -41691.98%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.20x
- Recent ROE (-72.64%) is above the historical average (-80.42%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | -264.19% | -211.46% | 0.48x | 2.63x | $-26.56 Million |
| 2012 | -31.02% | -13.07% | 1.05x | 2.26x | $-5.83 Million |
| 2013 | -36.99% | -833.98% | 0.04x | 1.15x | $-46.30 Million |
| 2014 | -21.60% | -1468.12% | 0.01x | 1.06x | $-86.78 Million |
| 2015 | -34.99% | -1090.62% | 0.03x | 1.06x | $-150.92 Million |
| 2016 | -27.66% | -1339.71% | 0.02x | 1.04x | $-104.01 Million |
| 2017 | -32.00% | -1579.53% | 0.02x | 1.06x | $-93.17 Million |
| 2018 | -39.12% | -962.78% | 0.04x | 1.07x | $-87.23 Million |
| 2019 | -157.93% | -1387.09% | 0.10x | 1.09x | $-184.65 Million |
| 2020 | -57.41% | -784.18% | 0.06x | 1.15x | $-49.46 Million |
| 2021 | -374.78% | -12925.47% | 0.02x | 1.47x | $-262.62 Million |
| 2022 | 67.03% | 509.01% | 0.12x | 1.09x | $146.48 Million |
| 2023 | -42.53% | -25337.96% | 0.00x | 1.10x | $-101.40 Million |
| 2024 | -72.64% | -41691.98% | 0.00x | 1.20x | $-100.55 Million |
Industry Comparison
This section compares Chimerix Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Chimerix Inc (CMRX) | $121.68 Million | -264.19% | 0.20x | $686.96 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |